Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health, Inc. (TDOC) Form 144 shows an insider intends to sell 2,383 common shares acquired by restricted stock vesting and held for compensation. The shares are scheduled for sale through Fidelity Brokerage Services on the NYSE with an aggregate market value of $18,075.77 based on the filing. The filer reports prior small open-market sales during June totaling 6,532 shares for gross proceeds of $45,018.22. The securities were acquired and the vesting/compensation payment occurred on the same date indicated in the filing. The filing includes the signer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Teladoc Health, Inc. (TDOC) Form 144 summary: This notice reports a proposed sale of 4,700 common shares through Fidelity Brokerage Services with an aggregate market value of $35,650.91, to be executed approximately on 09/02/2025 on the NYSE. The shares were acquired on 08/29/2025 as restricted stock vesting and were paid as compensation. The filing also discloses a prior sale by the same account: 4,653 shares sold on 06/02/2025 for $31,919.58. The filing includes the total number of shares outstanding reported as 176,690,662 and contains the required certification that the seller is not aware of undisclosed material adverse information.
Form 144 filed for Teladoc Health, Inc. (TDOC) by a selling person reporting a proposed sale of 3,998 shares of common stock through Fidelity Brokerage Services on the NYSE with an aggregate market value of $30,326.03. The filer states the shares were acquired on 08/29/2025 via restricted stock vesting as compensation and that payment was completed on that date. The notice lists one sale in the prior three months: 3,958 shares sold on 06/02/2025 for $27,151.88. The signer certifies no undisclosed material adverse information.
Teladoc Health, Inc. (TDOC) Form 144 shows an insider sale notice for 5,867 common shares, with an aggregate market value of $44,502.95, reported for an approximate sale date of 09/02/2025 on the NYSE. The shares were acquired by restricted stock vesting on 08/29/2025 and are being sold as compensation. The filer also reported a prior sale of 5,808 shares on 06/02/2025 for gross proceeds of $39,842.88. Outstanding shares are listed as 176,690,662, indicating the disclosed transactions represent a very small fraction of total shares.
Form 144 notice for Teladoc Health, Inc. (TDOC) shows a proposed sale of 12,846 common shares with an aggregate market value of $97,440.77 and an approximate sale date of 09/02/2025 on the NYSE. The filing reports the shares were acquired on 08/29/2025 through restricted stock vesting from the issuer and the payment nature is listed as compensation, indicating these are insider-awarded shares becoming eligible for sale.
The filing also discloses a sale by Mala Murthy of 13,856 shares on 06/02/2025 with gross proceeds of $95,052.16. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer. Shares outstanding are reported as 176,690,662.
TDOC Q2 2025 10-Q highlights:
- Revenue slipped 1.6 % YoY to $631.9 m; six-month revenue down 2.1 % to $1.26 bn. U.S. contributed 82 % of sales.
- Losses narrowed sharply. Q2 net loss was $32.7 m (-$0.19/sh) versus -$837.7 m (-$4.92/sh) a year ago, mainly because 2024 contained a $790 m goodwill charge. YTD loss is -$125.7 m (-$0.72/sh) versus -$919.6 m.
- Operating efficiency improved: EBITDA ex-items rose to $69.3 m vs. $89.5 m LY but YTD cash from ops increased to $107.4 m (+10 %). Advertising & marketing trimmed 1.6 %.
- Balance-sheet shifts: Cash fell to $679.6 m from $1.30 bn after $550.6 m retirement of 2025 convertible notes. Only $1 bn 1.25 % 2027 notes remain outstanding. Equity slipped 4.6 % to $1.42 bn; debt-to-equity now 0.70x.
- Intangibles & goodwill: New $59.1 m goodwill from Catapult Health was fully impaired, bringing total YTD impairment to the same amount versus $790 m LY. Intangibles amortization was $88.7 m for the quarter.
- Segment view: Integrated Care revenue +3.7 % YoY while BetterHelp -9.3 %. Integrated Care generated $57.5 m Adjusted EBITDA; BetterHelp $11.9 m.
- Liquidity backstop: On 17 Jul 2025 company executed a new five-year $300 m secured revolving credit facility with variable SOFR+2.75–3.25 % pricing.
Key takeaways: Profitability metrics and cash generation improved despite modest top-line softness, but cash reserves contracted materially after note redemptions and goodwill impairments continue to weigh on equity.
Form 4 snapshot: Teladoc Health, Inc. (TDOC) disclosed that director Jason Eric Evans converted restricted stock units (RSUs) into 1,016 shares of common stock on 20 June 2025. The transaction was coded “M,” indicating the exercise or conversion of a derivative security.
Following the transaction, Evans’ direct holdings in TDOC increased to 7,113 shares. His remaining unvested/undelivered derivative position stands at 5,082 RSUs. The RSUs originated from a 20 September 2023 grant of 12,195 units that vest one-third after one year and the balance in eight equal quarterly instalments.
No sale of shares was reported and no cash price was listed, implying a cost-free share settlement typical of RSU conversions. The filing contains no information on TDOC’s current operational performance, earnings, or other corporate events.
In sum, the Form 4 records a routine equity settlement that modestly increases insider share ownership but does not represent a market-moving development for Teladoc Health.
FAQ
What is the current stock price of Teladoc Health (TDOC)?
What is the market cap of Teladoc Health (TDOC)?
